- Home
- GNLX
GNLX
Genelux Corporation
as 06-20-2025 3:36pm EST
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | WESTLAKE VILLAGE |
| Market Cap: | 96.6M | IPO Year: | 2023 |
| Target Price: | $17.75 | AVG Volume (30 days): | 146.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.88 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.60 - $5.88 | Next Earning Date: | 08-13-2025 |
| Revenue: | N/A | Revenue Growth: | -95.29% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Genelux Corporation (GNLX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Yu Yong | GNLX | VP, Clinical Trial Operations | May 12 '25 | Sell | $2.92 | 5,579 | $16,290.68 | 47,640 | |
| Zindrick Thomas | GNLX | President and CEO | May 12 '25 | Sell | $2.92 | 10,764 | $31,430.88 | 191,447 | |
| Ryder Sean | GNLX | General Counsel | May 12 '25 | Sell | $2.92 | 4,475 | $13,067.00 | 47,621 | |
| Smalling Ralph | GNLX | Head of Regulatory | May 12 '25 | Sell | $2.92 | 1,259 | $3,676.28 | 34,760 | |
| Cappello Joseph | GNLX | VP, Pharmaceutical Development | May 12 '25 | Sell | $2.92 | 4,737 | $13,832.04 | 52,266 |
Latest Genelux Corporation News
GNLX Breaking Stock News: Dive into GNLX Ticker-Specific Updates for Smart Investing
Simply Wall St.
5 days ago
June 2025's Promising Penny Stocks For Savvy Investors
Zacks
19 days ago
Genelux Corporation (GNLX) Upgraded to Buy: Here's What You Should Know
GlobeNewswire
a month ago
Genelux Corporation Reports First Quarter 2025 Financial Results and Provides General Business Updates
GlobeNewswire
2 months ago
Genelux Corporation to Participate in a Fireside Chat at the Citizens Life Sciences Conference
Zacks
2 months ago
Is EUROFINS SCIENT (ERFSF) Outperforming Other Medical Stocks This Year?
Simply Wall St.
3 months ago
Genelux Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
GlobeNewswire
3 months ago
Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Zacks
3 months ago
Down -29.7% in 4 Weeks, Here's Why Genelux Corporation (GNLX) Looks Ripe for a Turnaround
Compare GNLX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GNLX Genelux Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.